Cargando…

Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period

BACKGROUND: Remdesivir (RDV) was approved for treatment of coronavirus disease 2019 (COVID-19), in May 2020 under US Food and Drug Administration emergency use authorization (EUA). Clinical outcomes related to RDV use in hospitalized patients during the EUA period are not well described. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elshaboury, Ramy H., Monk, Miranda M., Bebell, Lisa M., Bidell, Monique R., Adamsick, Meagan L., Gandhi, Ronak G., Paras, Molly L., Hohmann, Elizabeth L., Letourneau, Alyssa R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474339/ https://www.ncbi.nlm.nih.gov/pubmed/34589214 http://dx.doi.org/10.1177/20499361211046669

Ejemplares similares

61. Evaluation of the Impact of a Micafungin Time-Out Protocol for Hospitalized Patients
por: Williams, Kelsey N, et al.
Publicado: (2020)

1482. Local validation of the drug resistance in pneumonia clinical prediction score at a large academic medical center and a community hospital
por: Reinhard, Jennifer L, et al.
Publicado: (2020)

756. Impact of Infectious Diseases Pharmacists as Part of an Interdisciplinary OPAT Team Managing Vancomycin
por: Adamsick, Meagan L, et al.
Publicado: (2019)

A Case Series of Rifabutin Use in Staphylococcal Prosthetic Infections
por: Monk, Miranda, et al.
Publicado: (2022)

793. Rifabutin Use in Staphylococcal Prosthetic Material Infections: A Case Series
por: Monk, Miranda, et al.
Publicado: (2021)

Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study
por: Atallah, Natalie J., et al.
Publicado: (2022)

Emergency Use Authorization for Remdesivir and Its Potential Implications
por: Ochoa Chaar, Cassius Iyad, et al.
Publicado: (2020)

Recurrent Relatively Resistant Salmonella infantis Infection in 2 Immunocompromised Hosts Cleared With Prolonged Antibiotics and Fecal Microbiota Transplantation
por: Torres Soto, Mariam, et al.
Publicado: (2018)

Carbapenem-resistant Enterobacterales susceptibility patterns to new antimicrobials: A single-center analysis
por: Monk, Miranda, et al.
Publicado: (2023)

Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children
por: Chera, Alexandra, et al.
Publicado: (2022)

845. Clinical Outcomes in Patients Treated with High vs. Standard Dose Liposomal Amphotericin B for Invasive Mucormycosis
por: Valiante, Sarah, et al.
Publicado: (2023)

Remdesivir and COVID-19 – Authors' reply
por: Wang, Yeming, et al.
Publicado: (2020)

La FDA approuve le remdesivir comme traitement de la Covid-19
por: Manus, Jean-Marie
Publicado: (2020)

Colistin Nephrotoxicity: Meta-Analysis of Randomized Controlled Trials
por: Eljaaly, Khalid, et al.
Publicado: (2021)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

Remdesivir for the treatment of COVID-19: author's response
por: Lee, Todd C., et al.
Publicado: (2023)

Beta-lactam antibiotic test doses in the emergency department
por: Maguire, Michelle, et al.
Publicado: (2020)

If you don’t test, they will not treat: Impact of stopping preoperative screening for asymptomatic bacteriuria
por: Winkler, Marisa L., et al.
Publicado: (2023)

Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
por: Eastman, Richard T., et al.
Publicado: (2020)

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
por: Fortner, Andra, et al.
Publicado: (2021)

Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class
por: Bidell, Monique R., et al.
Publicado: (2020)

Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication
por: Pirzada, Rameez Hassan, et al.
Publicado: (2021)

Remdesivir: Intrahepatic cholestasis of pregnancy following compassionate use of remdesivir: case report
Publicado: (2020)

Evaluation of safety and effectiveness of remdesivir in treating COVID-19 patients after emergency use authorization study
por: Burhan, Erlina, et al.
Publicado: (2023)

Gut microbiome health and dysbiosis: A clinical primer
por: Bidell, Monique R., et al.
Publicado: (2022)

Public perceptions of the FDA’s marketing authorization of Vuse on Twitter/X
por: Lee, Sarah, et al.
Publicado: (2023)

Inclusion of patient-reported outcome instruments in US FDA medical device marketing authorizations
por: Matts, Sophia T., et al.
Publicado: (2022)

Perspectives on the FDA Draft Guidances for Use of Adipose Tissue
por: Johnson, Martin L., et al.
Publicado: (2017)

Environmental impact of the reported chromatographic methods for the determination of the first FDA-Approved therapy for COVID-19 Patients, Remdesivir: A comparative study
por: Ahmed, Amal B., et al.
Publicado: (2022)

FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017)

Outcomes from an inpatient beta-lactam allergy guideline across a large US health system
por: Blumenthal, Kimberly G., et al.
Publicado: (2019)

The authors respond to “Concerns about subgroup analyses and reason for stopping remdesivir trial”
por: Murthy, Srinivas
Publicado: (2022)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Remdesivir
por: Bakheit, Ahmed H., et al.
Publicado: (2023)

Compassionate Use of Remdesivir for Patients with Severe Covid-19
por: Grein, Jonathan, et al.
Publicado: (2020)

Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019
por: Montastruc, François, et al.
Publicado: (2020)

Compassionate use of remdesivir in children with COVID-19
por: Méndez-Echevarría, Ana, et al.
Publicado: (2020)

Remdesivir-associated bradycardia
por: Ching, Patrick R, et al.
Publicado: (2021)

Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola
por: Yan, Victoria C., et al.
Publicado: (2021)

The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication In Vitro and Decreases Viral Titers and Disease Progression in Syrian Hamsters
por: Shytaj, Iart Luca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2j7abtrr43t8tme1iueu2qmdaf